TIPALTI
19.9.2023 06:01:28 CEST | Business Wire | Press release
Tipalti, the leading finance automation platform, today announces the launch of a fully localised solution for the European market, along with a recently granted Electronic Money Institution (EMI) licence from De Nederlandsche Bank (DNB).
Manual finance processes continue to swallow over a third (34%) of European finance teams’ time.1 With its finance automation technology, Tipalti aims to eradicate this – enabling finance teams to have the time to contribute to strategic work that aids growth.
Building on its success in the UK, the new localised offering and licence enables Tipalti to offer a full spectrum of payment solutions and capabilities to more businesses across Europe. Overcoming inefficiencies, reducing friction in existing payment and administrative finance processes and increasing visibility and control will now be a reality for more businesses in the region, bringing speed and reliability of payments to a currently underserved market.
Tipalti is improving the operations of finance teams across all verticals with automation, including that of German-born Linkvertise. Maximilian Bentein, Head of Publisher at the online marketing service platform said: “Keeping over five-million content creators satisfied and paid on time is no easy task manually. With Tipalti, we have been able to automate the heavy load, keep our customers happy and achieve our ambitious growth plans in the region.
“As a German company with clients across Europe and the world, we’re delighted that this new, truly localised solution is now a reality - giving us an even easier way to handle our payouts and reach our goal in monetising worldwide creativity.”
Just two years after launching in Europe with a UK HQ, and one year after launching in Amsterdam, the unicorn valued at $8.3bn+, currently has over 100 customers in Europe, powered by a growing workforce of over 100 employees.
The launch of a European product and the EMI licence is a key stepping stone for Tipalti’s further European expansion into key European markets, including Germany and the Nordics, with expectations that the continent will bring in at least 20% of the company’s new business by the end of 2024.
Rob Israch, President of Tipalti, said: “We know that economic growth in Europe is predicted to be 1% for 2023 – which lags behind the US which saw 2.4% growth in the second quarter of this year.
“Now more than ever, businesses in the region need localised tools that eradicate manual processes, drive efficiency and give them a competitive edge - because time spent on manual finance processes is time spent away from strategic initiatives that drive growth.
“With our fully localised solution and strategic financial institution partnerships throughout Europe, Tipalti is in a strong position to help businesses achieve the sustainable growth needed. With a huge addressable market to serve, the opportunity for Tipalti in Europe is massive.”
Tipalti also announced that on 21st September, it will host its third annual Illuminate conference in which industry experts come together to discuss how automation, AI and innovation are shaping the future of finance. In addition to this, it will launch its expenses solution to deliver an easy-to-use product that handles employee global reimbursement needs, while connecting seamlessly with its end-to-end AP, mass payments, and procurement solutions. For more information, visit tipalti.com
About Tipalti
Tipalti is the only company handling both Global Partner Payments and Accounts Payable workflows for high-velocity companies across the entire financial operations cycle: onboarding and managing global suppliers, instituting procurement controls, streamlining invoice processing and approvals, managing employee expenses, executing payments around the world and reconciling payables data across a multi-subsidiary finance organisation. Tipalti enables companies to scale quickly by making payables strategic with operational, compliance, and financial controls. Companies can efficiently and securely pay thousands of partners, suppliers, and employees in 196 countries within minutes. Thousands of companies, such as Amazon Twitch, GoDaddy, Roku, WordPress.com, and ZipRecruiter use Tipalti to reduce manual workload by 80% and accelerate the monthly close by 25%, while strengthening financial and spend controls. For more information, visit tipalti.com/en-eu/.
1Tipalti commissioned Insight Avenue to conduct an independent study, comprising 500 interviews with Finance and AP leaders in the US, UK, Netherlands and Belgium. Interviewees were with high-growth businesses (revenue growth of 20% or more in the last 12 months) with 50 – 1,000 employees. Interviews were conducted during March 2023.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230918704176/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Thales Builds Cryptographic Security for the Age of AI and Post-Quantum Computing14.9.2026 09:00:00 CEST | Press release
Thales launches Luna 8, a new hardware security module (HSM) to provide future-ready, quantum resistant security to protect critical data and applications Powered by a Thales designed cryptographic processor, it delivers unparalleled performance, enhanced protection and the flexibility to adapt to new security needs Drawing on decades of cryptographic expertise, Luna 8 combines trusted security with support for emerging technologies, including post quantum cryptography According to the 2026 Thales Data Threat Report, the threat of Harvest Now, Decrypt Later (HNDL) attacks was the top-cited risk, with 59% of organizations reporting that they are prototyping and evaluating post-quantum cryptography (PQC) algorithms to prepare for the quantum era. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804748922/en/ ©Thales To help organizations turn this readiness into deployment,Thales, a global leader in advanced technologies, tod
U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations14.9.2026 09:00:00 CEST | Press release
Acceptance is based on pivotal Phase 3 data demonstrating rapid, durable and consistent skin clearance, including in high-impact sites, in a convenient once-daily pill Results from nearly 3,000 patients support potential for next-generation TYK2 inhibitor to redefine oral treatment expectations in psoriasis The Prescription Drug User Fee Act (PDUFA) target action date is in the first quarter of calendar year 2027 Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) under Priority Review for zasocitinib (TAK-279) for the treatment of adults with moderate-to-severe plaque psoriasis. Zasocitinib is an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, which demonstrated rapid, durable and consistent skin clearance in Phase 3 plaque psoriasis studies.1-3 Addressing unmet needs in psoriasis treatment “Despite progress in psoriasis care, there remains a need for highly
SWISSto12 and Mitsubishi Electric Corporation Announce Strategic Partnership14.9.2026 09:00:00 CEST | Press release
The Memorandum of Understanding (MoU) and additional contract signal a new phase of collaboration on market development in the Asia Pacific (APAC) region SWISSto12 today announced a memorandum of understanding (MoU) with Mitsubishi Electric Corporation (MELCO) (TOKYO: 6503) to pursue joint opportunities on advanced payloads, radio frequency (RF) products, and market development in Japan and the APAC region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914982179/en/ Masahiko Arai, Executive Officer and Group President, Defense & Space Systems, Mitsubishi Electric, and Dr. Emile de Rijk, Chief Executive Officer, SWISSto12 Joint opportunities will leverage MELCO’s extensive satellite system expertise and integration capabilities together with SWISSto12’s proprietary 3D-printing designs and processes that form the foundation of its next-generation payloads—smaller, lighter, highly performant, yet built in materially shorter
Focused Support Launches Cavok STRIKE to Expand Link-16 Participation Across the Joint Force14.9.2026 07:00:00 CEST | Press release
Extending Link-16 interoperability without platform-level hardware integration Focused Support LLC today announced the launch of Cavok STRIKE, an integrated software capability that expands the Link-16 tactical battlespace picture by enabling additional operational platforms to participate in the Link-16 network. Modern battlefields have increasing numbers of unmanned systems, sensors, and supporting platforms operating throughout the joint battlespace. The rapid proliferation of Group 1, 2, and 3 UAS, including both expendable and recoverable systems, has created a growing need to integrate these assets into the broader tactical network. Many of these platforms provide operationally relevant information but have historically remained outside the Link-16 network due to limitations in size, weight, power, platform integration complexity, or acquisition cost. Cavok STRIKE addresses this gap by enabling platforms to participate in the Link-16 network as non-command-and-control participant
Fujirebio Expands Access to Blood-based Neurology Testing in Brazil with ANVISA Market Authorization for Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma14.9.2026 07:00:00 CEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted market authorization for the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for use on the fully automated LUMIPULSE® G immunoassay platform in Brazil. “ANVISA authorization of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays marks another important step in our mission to expand access to reliable, clinically meaningful blood-based biomarkers for clinicians and patients worldwide,” said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “By making both neurological biomarker assays available to laboratories on a single, fully automated platform, we are helping support more informed clinical decision-making across a broad range of neurological conditions and throughout the diagnostic pathway.” The Brazilian ANVISA authorizations are based on the already CE marked in vitro diagnostics (IVD) approvals of these two
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom